The bar chart illustrates the proportion of a drug company’s total sales, per region, from 2002 to 2006.
Overall, Europe and Africa accounted for the largest share of the company’s sales throughout the period, despite experiencing a minor decline by the end. In contrast, South America maintained the lowest market share, while North America’s contribution steadily diminished and the figure for Asia increased during the given timeframe.
In detail, Europe and Africa generated 44% of the drug company’s total sales in 2002, after which it peaked at 48% in 2004; however, the figure then declined to 40% in 2006, yet Europe and Africa remained the leading region. Similarly, the drug company’s total sales in North America stood at 33% in 2002; however, the figure declined steadily to 21% by the end of the period.
Meanwhile, the proportion of the drug company’s sales in South America recorded the lowest figures throughout the timeline. It stood at 11% in 2002, hit its lowest point at 6% in 2004, before recovering to its initial level in 2006. As for Asia, this region contributed 12% to the drug company’s total sales at the outset before increasing dramatically over the period, reaching 28%, overtaking North America to become the second most significant contributor.